Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes
Authors' conclusion
GLP-1RAs and SGLT-2is may slow frailty progression through mechanisms independent of cardiovascular benefits. Future trials should confirm these preliminary findings.
Study context
- Population
- Older adults with T2D, 7% random sample of Medicare data
- Exposure
- GLP-1 RA, SGLT2i or SU vs DPP-4i
- Outcome
- Frailty progression, measured by a claims-based frailty index (CFI; range 0-1; higher = greater frailty)
- Follow-up
- 1 year
Methodological detailsnew-user design, 7% random sample of Medicare data, mediation analyses
- New-user design
- 7% random sample of Medicare data
- Mediation analyses
Main finding
As reported in the abstract
Mean CFI change
Each group vs DPP-4isMean CFI change (95% CI)
GLP-1RAs
−0.007(−0.011 to −0.004)
SGLT-2is
−0.005(−0.008 to −0.002)
Observational data: associations, not effects.
Further findings
Mediation by cardiovascular or safety events
- Associations minimally mediated by cardiovascular or safety events
Original publication
Sodium–Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. Diabetes Care. Published 13 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →